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Economic evaluation of an exercisecounselling intervention to enhance
smoking cessation outcomes: The Fit2Quit
trial
William Leung1,2*, Vaughan Roberts2, Louisa G. Gordon3, Christopher Bullen2, Hayden McRobbie4,
Harry Prapavessis5, Yannan Jiang2 and Ralph Maddison2,6

Abstract
Background: In the Fit2Quit randomised controlled trial, insufficiently-active adult cigarette smokers who contacted
Quitline for support to quit smoking were randomised to usual Quitline support or to also receive ≤10 face-to-face
and telephone exercise-support sessions delivered by trained exercise facilitators over the 24-week trial. This paper
aims to determine the cost-effectiveness of an exercise-counselling intervention added to Quitline compared to
Quitline alone in the Fit2Quit trial.
Methods: Within-trial and lifetime cost-effectiveness were assessed. A published Markov model was adapted, with
smokers facing increased risks of lung cancer and cardiovascular disease.
Results: Over 24 weeks, the incremental programme cost per participant in the intervention was NZ$428 (US$289
or €226; purchasing power parity-adjusted [PPP]). The incremental cost-effectiveness ratio (ICER) for seven-day point
prevalence measured at 24-week follow-up was NZ$31,733 (US$21,432 or €16,737 PPP-adjusted) per smoker
abstaining. However, for the 52% who adhered to the intervention (≥7 contacts), the ICER for point prevalence was
NZ$3,991 (US$2,695 or €2,105 PPP-adjusted). In this adherent subgroup, the Markov model estimated 0.057 and
0.068 discounted quality-adjusted life-year gains over the lifetime of 40-year-old males (ICER: NZ$4,431; US$2,993
or €2,337 PPP-adjusted) and females (ICER: NZ$2,909; US$1,965 or €1,534 PPP-adjusted).
Conclusions: The exercise-counselling intervention will only be cost-effective if adherence is a minimum of ≥7
intervention calls, which in turn leads to a sufficient number of quitters for health gains.
Trial registration: Australasian Clinical Trials Registry Number ACTRN12609000637246
Keywords: Economic evaluation, Exercise, Smoking cessation, Randomised controlled trial

Background
Smoking cessation is an important public health
challenge as it has intermediate and long-term health
benefits. Treatments to aid smoking cessation that are
widely available, accessible, and cost-effective would
therefore have great potential for public health
benefit.
* Correspondence: william.leung@otago.ac.nz
1
University of Otago, WellingtonPO Box 7343New Zealand
2
University of Auckland, Private Bag 92019, Auckland, New Zealand
Full list of author information is available at the end of the article

Despite the availability of effective treatments for
smoking cessation in many countries, the proportion of
people who successfully quit smoking is disappointingly
low [1, 2]. New approaches to sustain the implementation
of effective smoking cessation treatments are needed. One
option proposed as an aid for smoking cessation is the use
of exercise.
A recent Cochrane review of exercise interventions for
smoking cessation identified 20 randomised controlled
trials (n = 5870) with adequate follow-up (ie, at least six
months after the quit date) [3]. However, only 2 of the
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20 trials offered evidence that exercise aided smoking
cessation in the long term.
The authors of the Cochrane review highlighted a
number of methodological issues that have limited previous research: small sample sizes, lack of statistical power,
gender bias, lack of sufficient intensity or duration of the
intervention to positively affect smoking outcomes, and
reliance on structured supervised exercise regimens,
which limits scalability. Moreover, there is a complete
dearth of research to evaluate the cost-effectiveness of
this approach. The Fit2Quit trial was conducted in an attempt to address some of these methodological concerns
that were identified in an earlier version of the Cochrane
review, and to determine the cost-effectiveness of an
exercise-counselling intervention in addition to standard
smoking cessation support to enhance abstinence rates
compared to standard cessation support alone. The
objective of this paper is to present the within-trial (at
24-week follow-up) and lifetime cost-effectiveness analysis (using a Markov model) of the Fit2Quit trial. Additionally, we sought to identify how cost-effectiveness
would alter by investigating a subgroup of intervention
participants who adhered well to the intervention, that
is, those who may incur greater intervention costs but
potentially have greater quit rates. This may be of use in
directing future research and future counselling program
improvement.

Methods
Trial and intervention summary

The full details of the design and conduct of the Fit2Quit trial have been published elsewhere [4]. In brief, it
was a parallel group two-arm randomised controlled
trial conducted in New Zealand (NZ) between 2009 and
2012. Participants were randomised at a 1:1 ratio to
either receive an exercise intervention plus usual stop
smoking support, or to usual stop smoking support
alone (ie, Quitline). Table 1 shows the baseline characteristics of the trial participants (n = 906). There were no
significant differences in socio-demographic, smoking
and physical activity profiles at baseline between control
and intervention groups. All enrolled participants were
encouraged to set a quit date, and offered one-to-one
Quitline telephone support for three months, as well as
up to eight weeks of subsidised nicotine replacement
therapy.
Intervention group participants (n = 455) commenced
a six-month home and community-based exercise
programme delivered by Green Prescription (GRx)
services, delivered in 10 contacts (face-to-face and
telephone support sessions) over six months. GRx
involves a referral from primary care to agencies that
support physical activity [5]. In this trial however, participants randomised to the intervention group were referred
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by the researcher, without involving a General Practitioner. Once referred, trained exercise-facilitators (participant-support person [PSPs]) contacted participants and
offered telephone counselling to promote and support
exercise behavior. PSPs encouraged participants to work
towards a goal of partaking in ≥30 min of moderatevigorous aerobic-based exercise on most days of the week,
in line with the 1996 US Surgeon General’s recommendations [6].
The Fit2Quit trial results have been reported elsewhere
[7]. Smoking abstinence rates at 24 weeks were moderately high, but not statistically significantly different
between intervention and control groups. Of the 455 participants who were randomised to the intervention group,
52% (n = 236) completed at least seven of the ten intervention calls (median number of calls = 7, interquartile
range = 4─9), hereafter the adherent intervention group.
When compared with the control group, a significant
treatment effect on smoking cessation was found for those
who were in the adherent intervention group (OR 0.67,
95% CI 0.46 to 0.98, p = 0.04). Therefore, the economic
evaluation using a lifetime horizon is focused on this
adherent intervention group.
Outcomes data

Follow-up assessments were completed at 8 and
24 weeks after the nominated quit date. The primary
outcome was self-reported point-prevalence (ie, not a
single puff of a cigarette in the past seven days) at
24 weeks after the nominated quit date. At baseline and
24 weeks, self-reported physical activity levels were measured with the International Physical Activity Questionnaire – Long Form [8].
Health-related quality of life (HRQoL) was assessed
using the EQ-5D questionnaire with utility values
obtained from NZ tariff 2. Perfect health and death are
anchored at utilities of 1 and 0, respectively. ‘Imperfect’
health is valued at less than 1. The time spent at a
specific utility was used to generate a quality-adjusted
life-year (QALY). For example, if one year with advanced
stage lung cancer has a utility of 0.56, then half a year
with that disease is equivalent to 0.28 QALYs.
Table 2 details the key parameters used in the
model. Gender-specific continuous abstinence rates
and health-state utility values (for the ‘well and smoking’ states) have been taken from the trial data.
Epidemiological data were sourced from NZ life
tables, disease incidence rates, national databases and
international literature.
Health-state utilities for cardiovascular disease (CVD)
were taken from Sullivan et al. [9] where communitybased UK preferences were applied to EQ-5D descriptive
questionnaire responses in the US-based Medical
Expenditure Panel Survey (n = 79,522); coronary artery
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Table 1 Baseline characteristics for trial participants by group
Control
(n = 455)

Intervention adherent
(n = 236)

Intervention non-adherent
(n = 219)

37.3 ± 12.2

39.8 ± 12.4

35.2 ± 11.7

Male

207 (45.9)

105 (44.5)

103 (47)

Female

244 (54.1)

131 (55.5)

116 (53)

Age (years), mean ± SD
Sex, n (%)

Prioritised ethnicity, n (%)
NZ European

214 (47.5)

132 (55.9)

86 (39.3)

Māori

138 (30.6)

63 (26.7)

79 (36.1)

Pacific

55 (12.2)

15 (6.4)

32 (14.6)

Asian

11 (2.4)

5 (2.1)

8 (3.7)

Other

33 (7.3)

21 (8.9)

14 (6.4)

19.8 ± 9.2

20 ± 10.5

18.8 ± 8.1

Number of cigarettes/day, mean ± SD
Age of smoking onset (years), mean ± SD

15.5 ± 4.2

15.9 ± 4.9

15.1 ± 3.3

Years smoking continuously, mean ± SD

20.3 ± 11.9

21.7 ± 12.4

18.5 ± 11.5

Fagerström Test of Nicotine Dependence score, mean ± SD

5.6 ± 2

5.5 ± 1.9

5.5 ± 1.9

Yes

348 (77.2)

194 (82.2)

174 (79.5)

No

103 (22.8)

42 (17.8)

45 (20.6)

Never attempted to quit before

103 (22.8)

42 (17.8)

45 (20.6)

None

204 (45.2)

113 (47.9)

89 (40.6)

One

83 (18.4)

43 (18.2)

50 (22.8)

Two

28 (6.2)

19 (8.1)

18 (8.2)

Three

14 (3.1)

11 (4.7)

4 (1.8)

Previous quit attempts, n (%)

Number of quit attempts in previous 12 months, n (%)

Four or more

18 (4)

8 (3.4)

12 (5.5)

Do not know

1 (0.2)

0 (0)

1 (0.5)

One (very low)

8 (1.8)

2 (0.9)

5 (2.3)

Two

15 (3.3)

5 (2.1)

7 (3.2)

Three

97 (21.5)

30 (12.7)

53 (24.2)

Four

140 (31)

76 (32.2)

72 (32.9)

Five (very high)

190 (42.1)

123 (52.1)

81 (37)

Missing

1 (0.2)

0 (0)

1 (0.5)

Leisure time domain

601 ± 1,150

498 ± 799

621 ± 1,343

Work domain

3,557 ± 6,370

3,982 ± 6,532

4,015 ± 7,096

Confidence to quit, n (%)

Physical activity (MET minutes/week), mean ± SD

Active transport domain

437 ± 1,047

338 ± 1,025

531 ± 1,720

Domestic and garden domain

1,838 ± 2,877

1,665 ± 2,218

1,930 ± 3,032

Total walking

1,769 ± 2,838

1,844 ± 2,706

1,634 ± 2,534

Total moderate physical activity

3,191 ± 3,728

3,030 ± 3,460

3,624 ± 4,453

Total vigorous physical activity

1,472 ± 3,728

1,643 ± 4,008

1,832 ± 4,316

Total physical activity

6,481 ± 7,226

6,489 ± 7,389

7,132 ± 8,325

MET Metabolic Equivalent of Task
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Table 2 Data parameters in model
Model parameter

Mean (se)

Distribution

Source

29.8% (4.0%)

Beta

Trial

24.2% (3.0%)

19.7% (2.5%)

Beta

21%

a

[25]

30% cumulative

a

[26]

Annual incidence

eg 0.00180b

eg 0.00165b

Proportion – early stage lung cancer (I&II)

20%

a

[14]

Proportion – adv stage lung cancer (III&IV)

80%

a

[14]

Relative risk of lung cancer in ex-smokers vs. general population

eg 1.771

a

[14]

Male

Female

a) intervention – adherent group (n = 236)

35.2% (4.7%)

b) usual care
Relapse rate from 24 weeks (end of trial) to 12 months
Relapse rates after 12 months

Smoking
24-week point prevalence rates

Trial

Lung cancer
Beta

[27]

b

15 years after quitting
CVD
Annual incidence

eg 0.03095b

eg 0.01843b

Beta

[28]

Relative risk of CVD in smokers vs. general population

1.42 (0.031)

a

LogNormal

[29]

Relative risk of CVD in ex-smokers vs. smokers

0.71 (0.036)

a

LogNormal

[29]

a) pre-hospital death given a CVD event

18.1%

a

b) post-hospital death given a CVD event (≤28 days)

7.1%

a

Mortality

c) background mortality (annual)

b

[30]
[30]
b

eg 0.01071

eg 0.00715

0.800

a

Trial

continue smoking after end of trial

0.800

a

Assumption

abstain from smoking at end of trial

0.830

a

[11]

b) early stage lung cancer

0.73 (0.020)

a

Beta

[14]

adv stage lung cancer

0.56 (0.043)

a

Beta

[9]

Beta

[31]

Utility scores
a) well (no lung cancer or CVD)
baseline

c) weighted average CVD

0.611

[9, 10]

Excess health system costs (NZ$)
a) lung cancer, first year of diagnosis
lung cancer, subsequent annual costs before death
lung cancer, last six months before cancer death
b) CVD, first year of diagnosis if hospitalised
CVD, last six months before CVD death

eg 23,970b

eg 22,256b

Gamma

[13]

eg 4,341b

Gamma

[13]

eg 16,615

b

eg 20,300

Gamma

[13]

eg 11,327b

eg 10,189b

Gamma

[13]

b

b

Gamma

[13]

b

eg 5,375

b

eg 17,573

eg 11,048

NZ$1 = US$0.68 = €0.53
a
Same value for both sexes
b
Age/time-dependent values used in tables. If no other details are given, then the example is for a 65-year-old individual

disease (0.629), cerebrovascular disease and stroke (0.649),
congestive heart failure (0.493), and peripheral vascular
disease (0.657). Each disease state was then weighted by
their proportional incidence in the National Minimum
Dataset (NMDS) [10] of NZ CVD hospital admissions,
respectively 54.9, 21.9, 17.6, and 5.6%, to give a composite
CVD utility of 0.611.

It was assumed that the utility after quitting smoking,
and being CVD and lung cancer free, would improve by
0.03: Tillman and Silcock [11] noted this difference
between smokers (0.75) and ex-smokers after 5 years
abstinence (0.78) using the EQ-5D (n = 1,623). Similarly,
Xie et al. [12] reported a difference of 0.04 in EQ-5D
utilities between those not smoking 0.88 and those
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smoking 0.84 in the Medical Expenditure Panel Survey
data (n = 39,680).

Cost data

Costs gathered for the trial consisted of those from the
GRx-related intervention and the programme set-up.
The latter comprised the training costs for the intervention PSP, and PSP staff salary costs. The total training
costs were amortised over all the participants in the
intervention arm. Although referral to the GRx service
was by researcher in the trial, the cost of GP referral is
included. The cost per participant for Quitline was taken
from their 2013 annual report.
Out-of-trial cost data by age, gender, and disease were
estimated from the NZ HealthTracker database (Table 2).
This database is a linkage system for all nationally
collected health events, linked together by a personal
unique identifier (National Health Index number). Each
health event is linked to a unit resource cost, these include
inpatient hospitalisations, outpatient attendance, laboratories, pharmaceuticals and (average capitation only from)
general practice. Excess health system costs (healthcare
costs above that for the healthy population) by age and
gender, were calculated for the first year of diagnosis, subsequent annual costs (lung cancer only), and in the final
six months of life for the disease states modelled [13].
Costs were reported in NZ$, net of Goods and Sales
Tax, at 2012 base prices; they were inflated to 2012 price
levels, where necessary, using the Consumer Price Index.
Purchasing power parity exchange rates were used to
convert currencies. The economic analysis took a NZ
health system perspective.

Fig. 1 State transition diagram
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Markov model

The Markov model aimed to estimate the lifetime
incremental costs and QALYs of adding the intervention
to usual care. Trial costs and outcomes were used to
parameterise this model.
In the base case, separate male and female cohorts
were tracked from the age of 40 (the approximate
average age of trial participants) until age 100. Two
strategies were modeled; individuals either participated
in usual care alone (Quitline) or the Fit2Quit intervention in addition to usual care.
Cohorts, starting in the ‘well’ state (Fig. 1), faced
different probabilities of quitting smoking taken from
the trial; relapse rates were included after continued
abstinence at 24-week follow-up to 12 months, and in
the three years beyond a successful quit attempt. The
risk of developing lung cancer or CVD varied. Tunnel
features have been built into the model for the lung
cancer states to ensure that the risk of cancer progression or death is dependent upon the duration
since diagnosis. For CVD, an assumption was made
that an individual can have increased excess health
system costs only in the year of diagnosis and death
but they will have a permanently reduced HRQoL
once they enter the CVD health state.
The Markov model is an extension of the smoking
cessation model presented in Gordon et al. [14]. A
CVD health state, NZ-specific epidemiological and
cost data, different EQ-5D utility values and relapse
pattern have been added. Readers are directed there
for a more detailed explanation of the lung cancer
component of the model, the structure of which
remains unchanged.

Leung et al. Tobacco Induced Diseases (2017) 15:21

Page 6 of 9

Analysis

The within-trial analysis was on an intention-to-treat
basis. In the Markov model, only analyses comparing the
adherent intervention group (defined as having 70% of
calls delivered [7]) vs. the usual care group were performed. All participants with missing smoking status
were considered to be smokers.
All future costs and health outcomes have been
discounted at 3.5% per annum. In scenario analyses, the
following were tested: a 0 and 5% discount rate for both
future costs and QALYs; and changing the initial age of
the cohort to 30, 50 and 60-years old.
The effects of variations to the parameters with plausible uncertainty in the base case were assessed using
one-way sensitivity analyses (±2 standard deviations or
20% either way of the mean estimate), and simultaneously using probabilistic sensitivity analyses with Monte
Carlo simulation and 1000 repetitions. Beta, log-normal,
and gamma distributions were used for probabilities,
relative risks, and costs, respectively (Table 2).
Incremental cost-effectiveness ratios (ICERs) were
calculated to summarise the additional cost per unit of
health benefit gained by switching from usual care to the
intervention. For the trial analysis, the ICERs only
included the programme costs, as additional costs to the

health sector over those 24 weeks were not collected. All
analyses were conducted using TreeAge Pro 2014 and
Stata SE v11. Statistical tests were two-tailed and a 5%
significance level was used. The Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
was adhered to [15].

Results
Within-trial cost-effectiveness

Descriptive data of the quit rates, HRQoL, leisure-time
physical activity outcome measures and trial costs used
for the cost-effectiveness analysis are presented in
Table 3. Leisure-time physical activity showed a significant between-group change from baseline of 219 MET
mins per week (adjusted difference) in favour of the
intervention (p = 0.01). The average total cost per
participant for the intervention group was NZ$ 623 and
in the control arm was NZ$ 195.
Over the 24-week follow-up, after adjustment for baseline HRQoL, there was a non-significant gain of 0.001
QALYs (95% CI: −0.006 to 0.008) in favour of the intervention, giving an ICER of NZ$ 451,000 per QALY
gained. The ICER for 7-day point prevalence measured

Table 3 Trial outcomes and costs
Intervention (n = 455)

Usual care (n = 451)

Difference

Mean (se)

Mean (se)

Mean (95% CI)

23.1% (2.0%)

21.7% (1.9%)

1.3% (−4.1 to 6.8%)

Baseline

0.792 (0.01)

0.800 (0.01)

−0.008 (−0.035 to 0.019)

24-week follow-up

0.800 (0.01)

0.803 (0.01)

−0.002 (−0.029 to 0.025)

526 (69)

307 (66)

219 (53 to 386)

Quantity

Unit cost

2012 NZ$

Source

a) training for PSPs provided by investigators (trainer hours)

9

125

1,125

Trial

b) PSP salary incl. 25% overhead

2

75,000

150,000

Trial

Outcomes
Quit rates at 24-week follow-up
Point prevalence
EQ-5D utility scores

Leisure-time physical activity (MET mins/week)
Change from baseline
Costs
Intervention, programme costs

Intervention, cost per participant (n = 455)
a) PSP training costs per Fit2Quit participant

2.47

Trial

b) PSP salary

329.67

Trial

c) GP visit for Green Prescription
d) pedometer

1

e) Quitline

1

Usual care, Quitline cost per participant (n = 451)
NZ$1 = US$0.68 = €0.53
MET Metabolic Equivalent of Task, PSP participant-support person

30.44

65.00

Estimate

30.44

Trial
[32]

195.33

195.33

Total

622.91

Total

195.33

[32]
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at 24-week follow-up was NZ$ 31,733 per smoker
abstaining. Both values are unlikely to be considered
cost-effective.
For the 52% who adhered to the intervention, the
ICER for 7-day point prevalence measured at 24-week
follow-up was NZ$ 3,991 per smoker abstaining – with
32.2% (se = 3.0%) abstaining in the adherent group.
Lifetime cost-effectiveness for the adherent intervention
group

In the Monte Carlo simulations, for a cohort with a
starting age of 40 years, the adherent intervention participants compared with the control group gained 0.057
(males) and 0.068 (females) discounted QALYs till age
100 (Table 4). The ICERs were NZ$ 4,431 and NZ$
2,909 per QALY gained for males and females respectively. At a threshold of NZ$ 20,000 per QALY gained,
there was an 86% (males) and 90% (females) probability
that the Fit2Quit intervention is cost-effective. In oneway sensitivity analyses of the base case, the main driver
of uncertainty was the 12-month quit rates with other
variables only having a minor impact.
In scenario analyses, when varying the initial age of
the cohort, discounted incremental QALYs were marginally higher, discounted incremental costs were lower and
thus ICERs were more favourable for older cohorts. The
probability that the intervention was cost-effective at
NZ$ 20,000 per QALY gained ranged from 78 to 90% in
these analyses.

Discussion
To our knowledge, this is the first published costeffectiveness analysis of an exercise-counselling intervention for smoking cessation. Positive effects were

observed for those who adhered to the intervention, and
for this subgroup it is likely to be cost-effective compared to usual care for increasing quit rates.
This study has several strengths; baseline prognostic
factors were well-balanced, it is the largest study of
its kind and the intervention was conservatively
costed. For example, the intervention included an expensive NZ$ 30 Yamax SW-700 pedometer, which
may not be necessary in practice as pedometer apps
are now widely available for smartphones. The cost of
GP referral was also included, although this was not
necessary in the trial.
The study aimed to leverage existing national delivery
services for both smoking cessation and physical activity
promotion. The intervention was effective for increasing
leisure-time physical activity. Physical activity is beneficial for a wide range of other health risks and outcomes
such as depression, Type 2 diabetes, CVD and various
cancers [16]. Therefore it is important that physically inactive or insufficiently active people who smoke are referred to programs to increase activity levels.
If the intervention could be targeted at those who
would be willing to commit to seven or more intervention calls (the adherent group), the intervention may be
more effective and probably cost-effective over 24 weeks
compared to Quitline alone. Further, over the lifetime of
the 40-year-old cohort (who were adherent to the intervention), Markov modelling suggests that the intervention may be cost-effective in improving HRQoL. These
findings highlight the need to identify smokers who want
to quit and screen for readiness to exercise to truly realise
the benefits of such an approach and maximize smoking
cessation outcomes: issues identified earlier [17].
There are limitations to this economic evaluation.
First, verification of quit status was not undertaken due

Table 4 Lifetime cost-effectiveness for the adherent group
Adherent group

40-year-old male

Base case

Intervention

40-year-old female
Usual care

Difference

Intervention

Usual care Difference

Mean cost per person (NZ$)

9,952

9,700

253

11,032

10,833

199

QALYs gained per person

16.680

16.623

0.057

17.398

17.330

0.068

ICER per QALY (NZ$)

4,431

2,909

Probability cost effectivea

0.860

0.902

Scenarios

Incr. costs (NZ$) Incr. QALYs ICER (NZ$) Probability
Incr. costs (NZ$) Incr. QALYs ICER (NZ$) Probability
cost effectivea
cost effectivea

0% discount rate for costs & QALYs −68

0.158

Dominant 0.894

−220

0.186

Dominant 0.893

5% discount rate for costs & QALYs 310

0.042

7,404

0.831

272

0.051

5,371

0.886

30-year-old cohort

307

0.055

5,633

0.879

275

0.061

4,521

0.895

50-year-old cohort

189

0.064

2,942

0.858

238

0.070

3,419

0.847

60-year-old cohort

128

0.065

1,976

0.777

203

0.069

2,962

0.814

at NZ$ 20 k per QALY. NZ$1 = US$0.68 = €0.53
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year

a
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to the use of telephone-based assessments. Previous reviews of smoking cessation studies have shown that rates
of misreporting of smoking abstinence are generally less
than 5% [18]. Second, using the Markov model, the
CVD and lung cancer states were mutually exclusive,
and other (non-lung) cancers and respiratory diseases
were not modeled. This may underestimate the impact
of the intervention on future health outcomes and
healthcare costs averted. Our reported QALY gains are
below the benchmarks published by Stapleton and West
[19]. While the costs of those other co-morbidities have
not been modeled, their disutility may have been captured by the use of unadjusted population-based CVD
and lung cancer utility scores. Third, the Markov model
risk parameters for lung cancer were originally specified
for heavy smokers (≥20 cigarettes/day) and may not
apply to light smokers or those without the requisite
pack-years. Fourth, and finally this economic evaluation
using a lifetime horizon is limited to the adherent intervention subgroup: blanket provision for all smokers contacting
Quitline is unlikely to be cost-effective. As this adherent
subgroup was not prospectively defined, these results
should be interpreted with caution and viewed as hypothesis generating. However, we wanted to explore what
would make the intervention more cost-effective – higher
quitting through greater adherence was a possibility.
Further research should be focused on identifying
those who might be willing to commit to seven or
more intervention calls. Improvements to the Fit2Quit
intervention could include greater tailoring of the call
schedule, increased face-to-face contact, and the
provision of a support group. In addition, supplementing with electronic support, eg text messaging [20] or
a smoking cessation smartphone app [21], is highly
likely to improve cost-effectiveness [22]. Other options
could include a commitment contract [23], or funding/
provision through the workplace [24] and/or health insurance, where the productivity gains (not estimated
here) and reduced claims may provide an incentive to
intervene.

Conclusion
If the exercise-counselling intervention could be targeted
at those who would be willing to commit to seven or
more intervention calls, it may be cost-effective compared to Quitline alone – improving both abstinence
and leisure-time physical activity. Screening for readiness to exercise, an omission in the trial, would likely
have helped to identify those potentially adherent.
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